As discussed above (Section 3.2), visfatin acts in a bimodal and dose-dependent way [248,249]; thus, the increase in its levels observed in long-lasting obesity and T2D induces a diabetic phenotype in pancreatic islets [50]. This evidence concerns the gene NAMPT and obesity due to melanocortin 4 receptor deficiency.